Panitumumab injection
Products billed under this code include Vectibix.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vectibix.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vectibix | Amgen Inc | 55513-0954-01 | 10 | $1,832.75 |
| Vectibix | Amgen Inc | 55513-0954-21 | 10 | $1,832.75 |
| Vectibix | Amgen Inc | 55513-0956-01 | 40 | $7,331.00 |
| Vectibix | Amgen Inc | 55513-0956-21 | 40 | $7,331.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $183.275 | +$1.086 | 10 MG | Panitumumab injection | v1, posted September 17, 2026 |
| 3Q26 | $182.189 | +$7.803 | 10 MG | Panitumumab injection | v1, posted September 15, 2026 |
| 2Q26 | $174.386 | +$0.713 | 10 MG | Panitumumab injection | v1, posted September 15, 2026 |
| 1Q26 | $173.673 | +$0.643 | 10 MG | Panitumumab injection | v1, posted September 15, 2026 |
| 4Q25 | $173.03 | +$0.481 | 10 MG | Panitumumab injection | v1, posted September 8, 2026 |
| 3Q25 | $172.549 | +$7.626 | 10 MG | Panitumumab injection | v1, posted March 10, 2026 |
| 2Q25 | $164.923 | −$0.79 | 10 MG | Panitumumab injection | v1, posted March 10, 2026 |
| 1Q25 | $165.713 | +$6.387 | 10 MG | Panitumumab injection | v1, posted December 19, 2025 |
| 4Q24 | $159.326 | +$0.64 | 10 MG | Panitumumab injection | v1, posted June 11, 2025 |
| 3Q24 | $158.686 | +$7.448 | 10 MG | Panitumumab injection | v1, posted June 11, 2025 |
| 2Q24 | $151.238 | +$0.579 | 10 MG | Panitumumab injection | v1, posted March 11, 2025 |
| 1Q24 | $150.659 | +$0.942 | 10 MG | Panitumumab injection | v1, posted December 19, 2024 |
| 4Q23 | $149.717 | +$0.008 | 10 MG | Panitumumab injection | v1, posted October 10, 2024 |
| 3Q23 | $149.709 | +$7.288 | 10 MG | Panitumumab injection | v1, posted June 5, 2024 |
| 2Q23 | $142.421 | −$1.089 | 10 MG | Panitumumab injection | v1, posted February 23, 2024 |
| 1Q23 | $143.51 | +$3.84 | 10 MG | Panitumumab injection | v1, posted December 6, 2023 |
| 4Q22 | $139.67 | +$2.705 | 10 MG | Panitumumab injection | v1, posted June 22, 2023 |
| 3Q22 | $136.965 | +$6.178 | 10 MG | Panitumumab injection | v1, posted June 9, 2023 |
| 2Q22 | $130.787 | +$0.38 | 10 MG | Panitumumab injection | v1, posted December 14, 2022 |
| 1Q22 | $130.407 | +$0.028 | 10 MG | Panitumumab injection | v1, posted June 8, 2022 |
| 4Q21 | $130.379 | +$1.795 | 10 MG | Panitumumab injection | v1, posted June 2, 2022 |
| 3Q21 | $128.584 | +$4.711 | 10 MG | Panitumumab injection | v1, posted June 2, 2022 |
| 2Q21 | $123.873 | −$0.292 | 10 MG | Panitumumab injection | v1, posted March 1, 2022 |
| 1Q21 | $124.165 | – | 10 MG | Panitumumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.